ArticleJACC. Heart failure2015
Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals.
Article in JACC. Heart failure, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 80 citations in OpenAlex.
- Integrating hypertension screening at the time of voluntary HIV testing among adults in South Africa.PloS one · 2019Trial
- Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.Journal of acquired immune deficiency syndromes (1999) · 2018Trial
- Novel mediators of statin effects on plaque in HIV: a proteomics approach.AIDS (London, England) · 2018Trial
- The hidden link between HIV and cardiomyopathy: unraveling HIV's impact on the heart.Frontiers in cardiovascular medicine · 2025Review
- HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.Journal of the American Heart Association · 2024Article
- Lipoprotein(a) and Cardiovascular Disease in People Living With HIV: The Next Horizon.Journal of the American Heart Association · 2024Article
- HIV-Associated Heart Failure: Phenotypes and Clinical Outcomes in a Safety-Net Setting.medRxiv : the preprint server for health sciences · 2024Article
- Antiretroviral therapy and HIV-associated cardiovascular disease: a prospective cardiac biomarker and CMR tissue characterization study.ESC heart failure · 2024Article
- Effects of statins beyond lipid-lowering agents in ART-treated HIV infection.Frontiers in immunology · 2024Review
- The potential of cystatin C as a predictive biomarker in pulmonary hypertension.BMC pulmonary medicine · 2023Article
- High-throughput proteomic analysis reveals systemic dysregulation in virally suppressed people living with HIV.JCI insight · 2023Article
- Asymptomatic people with well-controlled HIV do not have abnormal left ventricular global longitudinal strain.Frontiers in cardiovascular medicine · 2023Article
- Evolution of myocardial oedema and fibrosis in HIV infected persons after the initiation of antiretroviral therapy: a prospective cardiovascular magnetic resonance study.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2022Article
- Human Immunodeficiency Virus Infection-Associated Cardiomyopathy and Heart Failure.Journal of personalized medicine · 2022Review
- Circulating biomarker correlates of left atrial size and myocardial extracellular volume fraction among persons living with and without HIV.BMC cardiovascular disorders · 2022Article
- Multiple substance use, inflammation and cardiac stretch in women living with HIV.Drug and alcohol dependence · 2022Article
- Prevention of heart failure, tachyarrhythmias and sudden cardiac death in HIV.Current opinion in HIV and AIDS · 2022Review
- Heightened levels of plasma growth differentiation factor 15 in men living with HIV.Physiological reports · 2022Article
- Increased biomarkers of cardiovascular risk in HIV-1 viremic controllers and low persistent inflammation in elite controllers and art-suppressed individuals.Scientific reports · 2022Article
- Progression of cardiac structure and function in people with human immunodeficiency virus.Echocardiography (Mount Kisco, N.Y.) · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
Abstract
objectivesThis study sought to determine whether biomarkers ST2, growth differentiation factor (GDF)-15, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity troponin I are elevated in patients infected with human immunodeficiency virus (HIV) and are associated with cardiovascular dysfunction and all-cause mortality.
backgroundHIV-infected patients have high rates of cardiovascular disease. Markers of myocardial stress may identify at-risk patients and provide additional prognostic information.
methodsBiomarkers and echocardiograms were assessed in 332 HIV-infected patients and 50 age- and sex-matched control subjects. Left ventricular systolic dysfunction was defined as ejection fraction <50%, diastolic dysfunction (DD) as stage 1 or higher, and pulmonary hypertension as pulmonary artery systolic pressure ≥35 mm Hg. Mortality data were obtained from the National Death Index.
resultsPatients with HIV had a median age of 49 years, and 80% were male. Compared with control subjects, HIV-infected patients had higher adjusted percent estimates of all biomarkers except ST2 and interleukin-6. Among HIV-infected patients, 45% had DD; only ST2 was associated with DD (relative risk [RR]: 1.36; p = 0.047). Left ventricular systolic dysfunction was rare in this cohort (5%). Pulmonary hypertension was present in 27% of HIV-infected patients and was associated with GDF-15 (RR: 1.18; p = 0.04), NT-proBNP (RR: 1.18; p = 0.007), and cystatin C (RR: 1.54; p = 0.03). Thirty-eight deaths occurred among HIV-infected patients over a median of 6.1 years. In adjusted analysis, all-cause mortality was independently predicted by ST2 (hazard ratio [HR]: 2.04; p = 0.010), GDF-15 (HR: 1.42; p = 0.0054), high-sensitivity C-reactive protein (HR: 1.25; p = 0.023), and D-dimer (HR: 1.49; p = 0.029). Relationships were unchanged when analyses were restricted to virally suppressed HIV-infected patients receiving antiretroviral therapy.
conclusionsAmong HIV-infected patients, ST2 and GDF-15 were associated with both cardiovascular dysfunction and all-cause mortality, and these variables may be useful at identifying those at risk for developing cardiovascular events and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.